Alnylam Pharmaceuticals
VP, Business Development (Finance)
Overview
Alnylam was founded in 2002 on a revolutionary vision and bold mission to lead the translation of the Nobel Prize-winning science of RNA interference (RNAi) into a new class of innovative medicines with the potential to transform the lives of people suffering from serious illnesses. In 2018, Alnylam's ONPATTRO was the first RNAi therapeutic ever approved in the US and EU for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. In addition, Alnylam has four investigational medicines in late-stage development. www.alnylam.com . Alnylam is proud to have been recognized as one of The Boston Globe's Top Places to Work in 2015, 2016, 2017 and 2018 -- four years in a row!
Alnylam's business strategy is to develop and commercialize a broad pipeline of RNAi therapeutic products directed towards our four Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases and CNS/Ocular Diseases. Business Development has been and will continue to be an integral part of our short and long term growth strategy. We expect to enter into additional collaboration and licensing agreements as a means of obtaining resources, capabilities and funding to advance our investigational RNAi therapeutic programs and to further grow our business.
The Vice President of Business Development reports to Alnylam's Chief Operating Officer and leads a team of experienced business development professionals. The role is based at Alnylam's headquarters in Cambridge, MA.
Responsibilities
Requirements
Alnylam Pharmaceuticals is an EEO employer committed to an exciting, diverse, and enriching work environment.
* We are not accepting search firm or agency inquiries for this opportunity